Kezar Life Sciences (NASDAQ:KZR) Stock, Quote.Headers.trade-ideas

Kezar Life Sciences

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

pharma lab worker ai

Biotech

News

Health Care

General

Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases.

Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug

Lithium.Shutterstock

Commodities

Global

Janus Henderson Group plc Ordinary Shares

Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining.

As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits

Penny Stocks

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHL

AENT

ARBB

AVGR

CRDL

ELUT

FTEL

HSCS

KERN

KRKR

LIFW

MURF

NEPT

RNAZ

SEEL

UPTD

VINE

VINO

Gainers

Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.

Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

Kezar Life Sciences Inc

<p>BMO Capital  analyst Keith Bachman   maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Outperform and maintains $570 price target.</p>


Price Target

Analyst Ratings

HUBS

BMO Capital Maintains Outperform on HubSpot, Maintains $570 Price Target

<p><strong>Toronto-Dominion Bank Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>) shares are seeing positive movement Thursday. Here&#8217;s <a href="https://www.benzinga.com/news/24/09/40937551/td-bank-group-president-and-ceo-bharat-masrani-to-retire-april-10-2025-board-names-raymond-chun-as-s">what you need to know.</a></p>
<p><strong>What To Know</strong>: The bank revealed that<strong> Bharat Masrani</strong>, who has served as CEO for over a decade and spent 38 years at the institution, will retire on April 10 2025. Masrani&#8217;s tenure saw significant milestones but also faced challenges, particularly toward the end of his leadership, as TD dealt with an unraveling $13.4 billion acquisition of <strong>First Horizon Corp</strong> and investigations into lapses in money-laundering controls at U.S. branches.</p>
<p>In response to these developments, TD Bank Group&#8217;s Board of Directors has named <strong>Raymond Chun</strong>, currently Group Head of Canadian Personal Banking, as the successor. Chun will step into the role of Chief Operating Officer on November 1 2024, with responsibility for all business lines, before officially taking over as CEO on April 10 2025. This move is part of TD's ongoing efforts to strengthen its leadership and reassure stakeholders during a challenging period for the bank.</p>
<p><strong>What Else:</strong> The leadership transition is taking place while the bank grapples with investigations by the U.S. Department of Justice and financial regulators over its handling of money-laundering controls in its American branches—a division that Masrani had previously overseen. The fallout from these issues has led to the departure of several top executives in the bank&#8217;s legal and compliance departments, contributing to uncertainty about the company's direction.</p>
<p><strong>Price Action:</strong> TD shares were trading higher by 2.27% at $64.01 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="553" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100258/TD-1024x553.png" alt="" class="wp-image-556379" style="width:509px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100258/TD-1024x553.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100258/TD-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100258/TD-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100258/TD.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>See Also:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/real-estate/24/09/40939943/elon-musk-mark-zuckerberg-and-jay-z-take-out-mortgages-despite-their-billion-dollar-fortunes-heres-w">Elon Musk, Mark Zuckerberg And Jay-Z Take Out Mortgages Despite Their Billion-Dollar Fortunes – Here&#8217;s Why The Ultra-Wealthy Borrow</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em>.</p>


Stock Split

What's Going On With Toronto-Dominion Bank Today?

<p>BMO Capital  analyst Brian Pitz   maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and maintains $230 price target.</p>


AMZN

BMO Capital Maintains Outperform on Amazon.com, Maintains $230 Price Target

<p>Cantor Fitzgerald  analyst Louise Chen   reiterates Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) with a Overweight.</p>


Reiteration

ROIV

Cantor Fitzgerald Reiterates Overweight on Roivant Sciences

GLXG

Galaxy Payroll Group Shares Halted On Circuit Breaker To The Downside, Stock Now Down -36.8%

<p><strong>Galmed Pharmaceuticals Ltd</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares are surging Thursday after the company&nbsp;announced plans to broaden its drug development activities <a href="https://www.benzinga.com/pressreleases/24/09/n40935244/galmed-announces-an-expansion-of-its-activities-to-cancer-and-major-cardiometabolic-diseases">over the next two years</a>.</p>
<p><strong>What Happened:</strong> Galmed announced that it plans to expand its drug development activities by adding two additional programs.</p>
<p>One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers. The other program is expected to help discover new methods to allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis.</p>
<p>The clinical-stage biopharmaceutical company said it&nbsp;plans to release new data from in-vitro and ex-vivo studies on the aforementioned programs during the&nbsp;fourth quarter.</p>
<p>&#8220;The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers,&#8221; said <strong>Allen Baharaff</strong>, president and CEO of Galmed Pharmaceuticals.</p>
<p>&#8220;SCD1 is a key enzyme that critically regulates many physiological processes, thereby promoting the progression of cardiovascular, cancer and neurodegenerative diseases. We are leveraging on two decades of development of the most clinically advanced SCD1 inhibitor (Aramchol) to date as we broaden our drug development activities.&#8221;</p>
<p><strong>Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40939795/1-8m-bet-on-singular-genomics-check-out-these-3-stocks-executives-are-buying">$1.8M Bet On Singular Genomics? Check Out These 3 Stocks Executives Are Buying</a></strong></p>
<p>Galmed Pharmaceuticals is a very low-float stock with approximately 625,000 shares available for public trading, per&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The company also had a market cap of less than $4.5 million as of Wednesday's close.&nbsp;Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Thursday's surge.</p>
<p>Galmed&#8217;s average session volume over a 100-day period is approximately 1.711 million. Thursday&#8217;s trading volume has already crossed 16 million at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><strong>GLMD Price Action:</strong> <a href="http://benzinga.com/quote/glmd">Galmed shares</a> were up 53.6% at $10.60 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: 3844328 from Pixabay.</em></p>


GLMD

Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why

<p>Cantor Fitzgerald  analyst Louise Chen   reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

<p><strong>Vivos Therapeutics Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) shares are trading lower by 26.1% to $3.05 during Thursday&#8217;s session after the company announced a $4.3 million registered offering of 1.36 million shares of common stock at <a href="https://www.benzinga.com/pressreleases/24/09/g40935188/vivos-therapeutics-announces-pricing-of-4-3-million-registered-direct-offering-of-common-stock-pri">$3.15 per share</a>.</p>
<p>The direct offering is expected to close on September 20, pending standard closing conditions, and will generate approximately $4.3 million in gross proceeds. <strong>H.C. Wainwright &amp; Co</strong>. is the exclusive placement agent for the offering. </p>
<p>Vivos says the company plans to use the net proceeds for working capital and general corporate purposes. Additionally, no stock purchase warrants are included in the offering.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40937291/bank-stocks-hit-inflection-point-after-feds-50-basis-point-cut-analyst-reveal-top-p">Bank Stocks Hit Inflection Point After Fed&#8217;s 50 Basis Point Cut, Analyst Reveals Top Picks</a></strong></p>
<h2 class="wp-block-heading">Is VVOS A Good Stock To Buy?</h2>
<p>An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages  &#8211; like <a href="https://www.benzinga.com/quote/VVOS">Vivos Therapeutics</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.</p>
<p>These are known as capital allocation programs. Vivos Therapeutics does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.</p>
<p>For example, if you're looking to earn an annualized return of 23.1%, you'll need to buy a share of North American Finl 15 by the Sep. 30, 2024. Once done, you can expect to receive a nominal payout of $0.11 on Oct. 10, 2024.</p>
<p>Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/VVOS">Vivos Therapeutics</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, VVOS has a 52-week high of $48.79 and a 52-week low of $1.91.</p>


VVOS

Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today

<p>BMO Capital  analyst John McNulty   reiterates Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Outperform and lowers the price target from $254 to $252.</p>


BMO Capital Reiterates Outperform on Avery Dennison, Lowers Price Target to $252

<p>BMO Capital  analyst Tim Casey   maintains Rogers Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) with a Outperform and raises the price target from $67 to $70.</p>


BMO Capital Maintains Outperform on Rogers Communications, Raises Price Target to $70

<p><strong>Mobileye Global Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) stock was trading higher Thursday after <strong>Intel Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) said it does not plan to divest its majority interest <a href="https://www.intc.com/news-events/press-releases/detail/1711/statement-regarding-mobileye" target="_blank" rel="noreferrer noopener">in the company</a>. U.S. Fed rate cut also had a bearing on the <a href="http://U.S. Federal Reserve" target="_blank" rel="noreferrer noopener">stock price movement</a>.</p>
<p>Intel made the statement after winning a multi-year, multi-billion-dollar U.S. chipmaking deal from existing customer <strong>Amazon.com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) cloud unit and <a href="https://www.benzinga.com/news/24/09/40897994/whats-going-on-with-intel-stock-on-tuesday" target="_blank" rel="noreferrer noopener">U.S. semiconductor grant</a>.</p>
<p>Intel also won up to&nbsp;$3 billion in CHIPS and Science Act funding, in addition to the $8.5 billion in grants and $11 billion in loans the struggling chipmaker previously won under the act.</p>
<p><strong><em>Also Read:</em></strong><em> <a href="https://www.benzinga.com/news/24/09/40888884/intel-missed-out-on-playstation-6-chip-deal-to-amd-report" target="_blank" rel="noreferrer noopener">Intel Missed Out on PlayStation 6 Chip Deal to AMD: Report</a></em></p>
<p><figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19084609/newplot-15.png" alt="" class="wp-image-556163" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19084609/newplot-15.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19084609/newplot-15-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure></p>
<p>Intel stock is down 43% in the last 12 months as its foundry unit failed to capitalize on the AI shift.</p>
<p>Prior reports indicated Intel&#8217;s plans to divest up to 88% of its stake in the <a href="https://www.benzinga.com/m-a/24/09/40747080/intel-eyes-mobileye-stake-sale-amid-pressure-stock-slides" target="_blank" rel="noreferrer noopener">Israeli autonomous driving company</a>.</p>
<p>Mobileye Global stock is down 70% in the last 12 months as it slashed revenue guidance after posting a topline decline in the second quarter. The company also flagged impending challenges due to China's weak demand. </p>
<p>It expects fiscal 2024 revenue of $1.60 billion–$1.68 billion below the $1.87 billion analyst estimate.</p>
<p><strong>Price Action: </strong>MBLY stock is up 14.4% at $13.28 at last check Thursday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/m-a/24/09/40926078/nvidia-considers-165m-octoai-acquisition-aims-to-strengthen-ai-and-cloud-dominance" target="_blank" rel="noreferrer noopener">Nvidia Considers $165M OctoAI Acquisition, Aims to Strengthen AI and Cloud Dominance</a></strong></li>
</ul>
<p><em>Photo courtesy of Mobileye.</em></p>


Asset Sales

Tech

INTC

MBLY

What's Going On With Autonomous Driving Stock Mobileye Thursday?

<p>Bulls are stampeding across Wall Street on Thursday in the wake of the Federal Reserve&#8217;s decision to cut interest rates for the first time<a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead"> in over four years</a>.</p>
<p>The central bank&#8217;s bold move, a 50-basis-point cut, caught analysts off guard and sent the U.S. stock market to fresh record highs at the opening of Thursday&#8217;s session.</p>
<p>The S&amp;P 500 soared to a new all-time high, reaching 5,700 points. Similarly, the Dow Jones Industrial Average climbed to an unprecedented 42,000 points.</p>
<p>In the first 30 minutes of trading, the S&amp;P 500 and Dow Jones rose by 1.4% and 1%, respectively. The Nasdaq 100 climbed 1.5%, although the Russell 2000, representing small-cap stocks, outperformed with a surge of over 2%.</p>
<p>The market rally was primarily driven by the Magnificent Seven: <strong>Microsoft Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), <strong>Apple Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), <strong>NVIDIA Corp.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), <strong>Alphabet Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), <strong>Amazon Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), <strong>Meta Platforms Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and <strong>Tesla, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). Each of the Magnificent Seven are recording daily gains ranging from 1.5% to 4.5%, solidly in positive territory.</p>
<h3 class="wp-block-heading">Chart: S&amp;P 500 Hits Record Highs</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="447" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100943/image-155-1024x447.png" alt="" class="wp-image-556397" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100943/image-155-1024x447.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100943/image-155-300x131.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100943/image-155-768x336.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100943/image-155-1536x671.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19100943/image-155.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image: <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091924&amp;t=be2bearmibe3na1">Benzinga Pro</a></figcaption></figure></p>
<h3 class="wp-block-heading">Strong Labor Market Eases Slowdown Fears, Analysts Boost Rate-Cut Wagers</h3>
<p>Thursday&#8217;s economic data further boosted investor confidence. Weekly jobless claims came in well below expectations, suggesting a lower-than-expected trend of rising unemployment. </p>
<p>Continuing jobless claims also dropped more than expected, hinting at a potential absorption of long-term unemployed individuals into the job market. </p>
<p>This data alleviated concerns about rising unemployment and provided a more optimistic outlook for the economy.</p>
<p>Wall Street analysts quickly adjusted their expectations following the Federal Reserve&#8217;s rate cut. There is now growing anticipation of additional rate cuts, diverging from the cautious tone expressed in the Fed&#8217;s September &#8220;dot plot&#8221; and Chair <strong>Jerome Powell</strong>&#8216;s remarks during the press conference.</p>
<p>Notably, Goldman Sachs economist <strong>Jan Hatzius</strong> revised his forecast from expecting a 25-basis-point cut at every other meeting to predicting a rate cut at every meeting. He even left the door open for a back-to-back 50-basis-point reduction in November.</p>
<h3 class="wp-block-heading">Thursday&#8217;s 5 Top-Performing S&amp;P 500 Stocks</h3>
<p>Among the S&amp;P 500, the top five performers as of 10 a.m. ET were:</p>
<p><figure class="wp-block-table is-style-stripes"><br />
<table>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>1-day Return</strong></td>
</tr>
<tr>
<td><strong>Darden Restaurants, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NASDAQ">DRI</a>) </td>
<td>7.46</td>
</tr>
<tr>
<td><strong>Airbnb, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>)</td>
<td>5.27</td>
</tr>
<tr>
<td><strong>Cadence Design Systems, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>)</td>
<td>4.40</td>
</tr>
<tr>
<td><strong>Lam Research Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCRX#NASDAQ">LCRX</a>)</td>
<td>4.34</td>
</tr>
<tr>
<td><strong>NVIDIA Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>4.33</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<h3 class="wp-block-heading">Thursday&#8217;s 5 Top-Performing Dow Jones Industrial Average Stocks</h3>
<p>Among the Dow Jone, the top five performers were:</p>
<p><figure class="wp-block-table is-style-stripes"><br />
<table>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>1-day Return</strong></td>
</tr>
<tr>
<td><strong>Apple Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>3.02</td>
</tr>
<tr>
<td><strong>Salesforce, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NASDAQ">CRM</a>)</td>
<td>3.01</td>
</tr>
<tr>
<td><strong>The Goldman Sachs Group, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</td>
<td>2.80</td>
</tr>
<tr>
<td><strong>Caterpillar Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</td>
<td>2.71</td>
</tr>
<tr>
<td><strong>American Express Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</td>
<td>2.67</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40938732/wall-street-ramps-up-interest-rate-cut-bets-after-fed-meeting-the-hard-landing-crow">Wall Street Ramps Up Interest Rate Cut Bets After Fed Meeting: &#8216;The Hard-Landing Crowd Should Disperse,&#8217; Economist Says</a></strong></li>
</ul>
<p><em>Photo via Shutterstock. </em></p>


Analyst Color

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Federal Reserve

ETFs

AAPL

ABNB

CDNS

GOOG

GOOGL

LCRX

MSFT

NVDA

TSLA

S&P 500, Dow Jones Hit Record Highs: Magnificent 7 Add $400 Billion After Fed's Historic Interest Rate Cut

<p>Thursday,&nbsp;the FDA declined to approve <strong>Vanda Pharmaceuticals Inc.&#8217;s </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>)&nbsp;New Drug Application (NDA) of tradipitant for symptoms in gastroparesis, providing Vanda with a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40935243/fda-declines-to-approve-vandas-marketing-application-for-tradipitant-in-gastroparesis" rel="noreferrer noopener">Complete Response Letter (CRL)</a>.</p>
<p>Gastroparesis (means&nbsp;paralysis of the stomach) is&nbsp;a condition that slows down the stomach&#8217;s ability to empty its contents.</p>
<p>It is associated with severe nausea, vomiting, and difficulty finishing a normal meal.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/06/39530573/whats-going-on-with-vanda-pharmaceuticals-shares-today" rel="noreferrer noopener">What&#8217;s Going On With Vanda Pharmaceuticals Shares Today?</a></strong></p>
<p>The FDA has approved no effective treatment in over 40 years.</p>
<p>Vanda&#8217;s tradipitant application included evidence from two placebo-controlled studies, the results of which were published in peer-reviewed journals.</p>
<p>The&nbsp;CRL was conclusory in nature. It generally disregarded the evidence provided and instead suggested that Vanda conduct additional studies with a design and duration inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding and natural course of the disorder.&nbsp;</p>
<p>Furthermore, the FDA&#8217;s action was delayed by more than 185 days and failed to satisfy the Food Drug and Cosmetic Act (FDCA) requirements.</p>
<p>The FDCA requires that the FDA review a new drug application and provide either an approval or an opportunity for a hearing within 180 days of submission. In this case, the FDA failed to do either.</p>
<p>Despite the FDA&#8217;s disappointing action,&nbsp;Vanda believes that the tradipitant application has met the substantial evidence of efficacy standard and has a favorable benefit-risk profile for gastroparesis patients.&nbsp;</p>
<p>While Vanda has repeatedly requested that the FDA convene an expert advisory committee to review the application and advise the Commissioner on its approvability, the FDA has refused to do so.</p>
<p>The company added that several patients currently treated with tradipitant have filed a Citizen Petition urging the FDA to approve tradipitant for gastroparesis.</p>
<p>Vanda will continue to pursue the marketing authorization for tradipitant and support the expanded access program.</p>
<p>Vanda plans to submit a separate NDA for tradipitant to prevent vomiting in motion sickness later this year.</p>
<p><strong>Price Action:</strong> VNDA stock is down 7.68% at $4.57 at the last check on Thursday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/09/40937317/signing-day-sports-and-swifty-global-join-forces-in-all-equity-deal-whats-on-the-cards" target="_blank" rel="noreferrer noopener">Signing Day Sports And Swifty Global Join Forces In All-Equity Deal &#8211; What&#8217;s On The Cards?</a></strong></li>
</ul>


VNDA

FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies

<p><i>New offering allows employers with self-funded medical plans to manage the risk of high medical claim payouts</i></p>
<p>Prudential Financial, Inc. ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.prudential.com%2Fabout&amp;,%20esheet=54124569&amp;,%20newsitemid=20240919373614&amp;,%20lan=en-US&amp;,%20anchor=NYSE%3A+PRU&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">PRU</a>) has introduced a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprudential.scene7.com%2Fis%2Fcontent%2Fprudential%2F1081799_MedicalStopLoss_Video&amp;esheet=54124569&amp;newsitemid=20240919373614&amp;lan=en-US&amp;anchor=Stop+Loss+Insurance+product&amp;index=2&amp;md5=d31b07d257288220c647ba0a7590e606">Stop Loss Insurance product</a> aimed at helping protect companies with self-funded employee medical plans against catastrophic medical claim payouts.</p>
<p>With Stop Loss Insurance, employers can set a cap on their potential employee healthcare spend and transfer some of the claims volatility to The Prudential Insurance Company of America.</p>


Prudential Financial Introduces Stop Loss Insurance, New Offering Allows Employers With Self-Funded Medical Plans To Manage The Risk Of High Medical Claim Payouts

<p>Cantor Fitzgerald  analyst Sarah James   maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Overweight and lowers the price target from $37 to $25.</p>


PGNY

Cantor Fitzgerald Maintains Overweight on Progyny, Lowers Price Target to $25

<p><a href="https://thebearcave.substack.com/p/problems-at-verint-systems-vrnt" title="https://thebearcave.substack.com/p/problems-at-verint-systems-vrnt">https://thebearcave.substack.com/p/problems-at-verint-systems-vrnt</a></p>


Short Sellers

VRNT

Watching Verint Systems; The Bear Cave Research Issues Report On Co Titled "Problems at Verint Systems (VRNT)"

<p>Deep-pocketed investors have adopted a bullish approach towards Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNAP usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Snap. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 53% leaning bullish and 46% bearish. Among these notable options, 3 are puts, totaling $571,315, and 12 are calls, amounting to $1,019,657.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $12.0 for Snap over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Snap options trades today is 4280.14 with a total volume of 45,299.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Snap's big money trades within a strike price range of $7.0 to $12.0 over the last 30 days.</p>
<h3>Snap Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726756274_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNAP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.31</td>
<td>$1.19</td>
<td>$1.2</td>
<td>$11.00</td>
<td>$233.1K</td>
<td>9.6K</td>
<td>4.0K</td>
</tr>
<tr>
<td>SNAP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$10.00</td>
<td>$216.7K</td>
<td>3.8K</td>
<td>1.2K</td>
</tr>
<tr>
<td>SNAP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.7</td>
<td>$1.68</td>
<td>$1.7</td>
<td>$10.00</td>
<td>$214.4K</td>
<td>3.8K</td>
<td>1.2K</td>
</tr>
<tr>
<td>SNAP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.68</td>
<td>$1.67</td>
<td>$1.68</td>
<td>$10.00</td>
<td>$140.1K</td>
<td>3.8K</td>
<td>3.7K</td>
</tr>
<tr>
<td>SNAP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.21</td>
<td>$1.19</td>
<td>$1.19</td>
<td>$11.00</td>
<td>$121.6K</td>
<td>9.6K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Snap</h3>
<p>Snap owns one of the most popular social networking apps, Snapchat, claiming more than 400 million daily active users as of the end of 2023. Snap generates nearly all its revenue from advertising. While only about one quarter of users are in North America, the region accounts for about 65% of sales.</p>
<p>Having examined the options trading patterns of Snap, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Snap Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,954,519, the price of SNAP is up by 4.5%, reaching $10.11.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 33 days from now.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Snap options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

SNAP

Snap Unusual Options Activity For September 19

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Zillow Gr</strong>.</p>
<p>Looking at options history for Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 45% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $102,500 and 8, calls, for a total amount of $837,013.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $80.0 for Zillow Gr, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Zillow Gr stands at 4100.0, with a total volume reaching 3,788.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Zillow Gr, situated within the strike price corridor from $60.0 to $80.0, throughout the last 30 days.</p>
<h3>Zillow Gr Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726756269_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Z</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$6.75</td>
<td>$5.65</td>
<td>$6.75</td>
<td>$61.00</td>
<td>$168.7K</td>
<td>3.3K</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.25</td>
<td>$3.1</td>
<td>$3.21</td>
<td>$80.00</td>
<td>$159.4K</td>
<td>5.2K</td>
<td style="text-align: right;">771</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.65</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$70.00</td>
<td>$157.5K</td>
<td>15.0K</td>
<td style="text-align: right;">701</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$12.5</td>
<td>$12.1</td>
<td>$12.1</td>
<td>$60.00</td>
<td>$152.4K</td>
<td>4.1K</td>
<td style="text-align: right;">238</td>
</tr>
<tr>
<td>Z</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.25</td>
<td>$2.97</td>
<td>$3.12</td>
<td>$80.00</td>
<td>$78.0K</td>
<td>5.2K</td>
<td style="text-align: right;">270</td>
</tr>
</tbody>
</table>
</p>
<h3>About Zillow Gr</h3>
<p>Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.</p>
<p>Having examined the options trading patterns of Zillow Gr, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Zillow Gr</h3>
<ul>
<li>With a volume of 1,145,368, the price of Z is up 3.92% at $67.66. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>Professional Analyst Ratings for Zillow Gr</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $80.0.</p>
<ul>
<li>Showing optimism, an analyst from Wedbush upgrades its rating to Outperform with a revised price target of $80. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Zillow Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With Zillow Gr

SUA Natural Gas Storage 58B Vs 53B Est.; 40B Prior

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Duolingo</strong>.</p>
<p>Looking at options history for Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 0% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $93,400 and 5, calls, for a total amount of $460,298.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $220.0 to $330.0 for Duolingo over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Duolingo's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Duolingo's whale activity within a strike price range from $220.0 to $330.0 in the last 30 days. </p>
<h3>Duolingo Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726756263_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$13.0</td>
<td>$12.7</td>
<td>$12.7</td>
<td>$300.00</td>
<td>$203.0K</td>
<td style="text-align: right;">132</td>
<td style="text-align: right;">4</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$14.4</td>
<td>$12.9</td>
<td>$13.9</td>
<td>$330.00</td>
<td>$139.0K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$22.7</td>
<td>$19.1</td>
<td>$20.88</td>
<td>$240.00</td>
<td>$41.7K</td>
<td style="text-align: right;">228</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$40.0</td>
<td>$37.9</td>
<td>$40.0</td>
<td>$220.00</td>
<td>$40.0K</td>
<td style="text-align: right;">236</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DUOL</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$20.2</td>
<td>$17.3</td>
<td>$18.95</td>
<td>$270.00</td>
<td>$37.9K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Duolingo</h3>
<p>Duolingo Inc is a technology company that develops mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include The Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has three predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test.</p>
<p>Following our analysis of the options activities associated with Duolingo, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Duolingo</h3>
<ul>
<li>With a volume of 122,338, the price of DUOL is up 4.58% at $261.69. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 48 days.</li>
</ul>
<h3>Professional Analyst Ratings for Duolingo</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $260.5.</p>
<ul>
<li>Consistent in their evaluation, an analyst from DA Davidson keeps a Buy rating on Duolingo with a target price of $250. </li>
<li>Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Duolingo with a target price of $271. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Duolingo with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


DUOL

Spotlight on Duolingo: Analyzing the Surge in Options Activity

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kezar Life Sciences (KZR – Research Report), Fisher & Paykel Heal...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>A constellation of stocks beckons daring investors from the great expanse of the financial galaxy, where stars glitter with promise and fortunes wait to be discovered.</p>



<p>The first stop on the journey is a celestial body whose excellent recovery rates and record-breaking throughput suggest a gold mine of opportunities. Travelers discover the keys of management skill and operational excellence that drive its growth as they navigate its glistening expanse.</p>



<p>However, the journey doesn&rsquo;t end there. Instead, reach farther and come across the second one, a lighthouse of technical advancement in the universe of biotechnology. In this case, strategic alliances act as constellations that direct the course of its clinical trial and medication development.</p>



<p>But the trip still needs to go on. Explorers see autonomous driving solutions emerging in the future as they focus on <strong>Aurora Innovation</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aur-stock-quote/"><strong>AUR</strong></a>). The technology of the third one paves the path for the transportation revolution and redefines possibilities beyond the intergalactic roads of trade. </p>



<p>Learn how three notable individuals stand out and get enormous rewards.</p>



<h2>Galiano Gold (GAU)</h2>



<div><img width="300" height="199" src="https://investorplace.com/wp-content/uploads/2014/07/4-300x199.jpg" alt="gold mining stocks gold stocks gold prices"><div>Source: &copy;iStock.com/belchonock</div></div><p>The company&rsquo;s ability to achieve high metallurgical recovery rates and its effective use of milling capacity enhance <strong>Galiano Gold&rsquo;s </strong>(NYSEAMERICAN:<span><a href="https://investorplace.com/stock-quotes/gau-stock-quote/"><strong>GAU</strong></a></span>) market value. In Q4 2023, Galiano Gold used its milling operations to treat&nbsp;<a href="https://s24.q4cdn.com/325379252/files/doc_financials/2023/q4/Galiano-Q4-2023-Financial-Results-News-Release-Final.pdf" target="_blank">1.5 million metric tons&nbsp;</a>(Mt) of ore. This significant throughput helped the Asanko Gold Mine (<a href="https://investorplace.com/stock-quotes/agm-stock-quote/"><strong>AGM</strong></a>) achieve a new record in 2023 with a yearly throughput of 6.1 metric tons of ore. The steady rise in throughput indicates excellent operations and well-managed milling processes.</p>



<p>Additionally, the operations indicate that in Q4, the metallurgical recovery rate&nbsp;<a target="_blank" href="https://s24.q4cdn.com/325379252/files/doc_financials/2023/q4/Galiano-Q4-2023-Financial-Results-News-Release-Final.pdf">was 84%</a>. This high recovery rate shows how well the company&rsquo;s ore processing techniques extract gold from ore that has been mined. Profitability and gold yield maximization depend on effective recovery rates.</p>



<p>Furthermore, Galiano Gold produced 31,947 ounces of gold in Q4. As seen by the<a href="https://s24.q4cdn.com/325379252/files/doc_presentations/2024/Mar/15/march-2024-investor-update-final.pdf" target="_blank">&nbsp;134,077 ounces</a>&nbsp;produced in 2023, this amount adds to the general trend of rising output. Finally, this year&rsquo;s production surpassed the updated production projection&rsquo;s 120,000&ndash;130,000-ounce upper limit. Overall, such a steady output increase shows the business&rsquo;s operational expertise and ability to reach and exceed goals.</p>



<h2>Kezar (KZR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Performance is essential when assessing <strong>Kezar&rsquo;s</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/kzr-stock-quote/"><strong>KZR</strong></a></span>) valuation potential. Kezar had&nbsp;<a href="https://ir.kezarlifesciences.com/node/9311/pdf" target="_blank">$201.4 million in cash</a>&nbsp;as of 2023, as opposed to $276.6 million in 2022. The cash utilized in operations to progress preclinical research and development and clinical-stage activities was the main cause of the decline in cash reserves. The reduction in cash reserves reflects the company&rsquo;s expenditure on developing its pipeline, including clinical trials and research endeavors.</p>



<p>Notably, because of the upfront payment made as part of the partnership and license deal with <strong>Everest Medicines</strong>, Kezar declared revenue of&nbsp;<a href="https://ir.kezarlifesciences.com/node/9311/pdf" target="_blank">$7.0 million for 2023</a>. The revenue gained via collaborations demonstrates Kezar&rsquo;s capacity to use strategic alliances to diversify its revenue sources and support its operations.</p>



<p>Finally, Q4 2023 saw an increase in R&amp;D spending to&nbsp;<a href="https://ir.kezarlifesciences.com/static-files/8f9c8f76-3a57-410c-b2ee-c553fc6dd3ee" target="_blank">$22.6 million</a>&nbsp;from $14.9 million in 2022. R&amp;D costs increased from $51.0 million in 2022 to $85.7 million in 2023. Kezar is investing in the progress of its clinical projects, especially the PALIZADE and PORTOLA trials. Therefore, this is reflected in the notable rise in R&amp;D costs, demonstrating the company&rsquo;s dedication to medication research and innovation.</p>



<h2>Aurora (AUR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/09/shutterstock_2020356275-300x169.jpg" alt="a phone displaying the Aurora website in front of a computer screen displaying the company logo"><div>Source: T. Schneider / Shutterstock</div></div><p>Aurora&rsquo;s revenue development and market expansion are mainly due to its commercial advancement and solid client connections. The organization&rsquo;s capacity to obtain contractual obligations from clients, reliably arrange loads, and accrue substantial commercial mileage indicates the increasing recognition and acceptance of its self-driving trucking solutions.</p>



<p>Additionally, Aurora arranges more than <a href="https://d1io3yog0oux5.cloudfront.net/_751b143ca85d39516899d3fa5633e689/aurora/news/2024-02-14_Aurora_Announces_Fourth_Quarter_2023_90.pdf" target="_blank">100 loads each week</a>. This is indicative of Aurora&rsquo;s scalability and continuous demand for its services. Thus, weekly logs of about 25,000 commercial miles highlight the business&rsquo;s capacity usage and operational effectiveness even more.</p>



<p>Furthermore, the dependability and efficacy of Aurora&rsquo;s autonomous driving technology in actual commercial operations are demonstrated by completing over<a href="https://d1io3yog0oux5.cloudfront.net/_751b143ca85d39516899d3fa5633e689/aurora/news/2024-02-14_Aurora_Announces_Fourth_Quarter_2023_90.pdf" target="_blank">&nbsp;4,300 autonomous deliveries</a>&nbsp;with over 100% on-time performance. These performance indicators are essential for gaining clients&rsquo; trust and confidence. Hence, this opens doors to long-term collaborations and chances for revenue development.</p>



<p>Finally, in partnership with&nbsp;<strong>Continental</strong> (OTCPK:<strong>CTTAF</strong>), the design and architecture of the next Aurora Driver hardware generation have been completed. Therefore, finalizing hardware design milestones and delivering late-stage prototypes to the fleet are two examples of how partnerships with original equipment manufacturers (OEMs) have facilitated development.</p>



<p><em>On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a></em></p>
<div><p>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/from-pennies-to-fortunes-3-stocks-set-to-make-millionaires/">From Pennies to Fortunes: 3 Stocks Set to Make Millionaires</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

From Pennies to Fortunes: 3 Stocks Set to Make Millionaires

Kezar Life Sciences GAAP EPS of -$0.30

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Kezar Life Sciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/kzr-stock-quote/"><strong>KZR</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Kezar Life Sciences reported earnings per share of -30 cents. This was above the analyst estimate for EPS of -33 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/kzr-stock-earnings-kezar-life-sciences-for-q1-of-2024/">KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024

Kezar Life Sciences (KZR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju fro...

Buy Rating Affirmed for Kezar Life Sciences Amid Promising Clinical Trials and Strong Financial Position

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Kezar Life Sciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/kzr-stock-quote/"><strong>KZR</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Kezar Life Sciences reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -32 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/kzr-stock-earnings-kezar-life-sciences-for-q2-of-2024/">KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kezar Life Sciences (KZR – Research Report) and keeping the price target at $...

Buy Rating on Kezar Life Sciences Backed by Promising Zetomipzomib Clinical Trials

TD Cowen analyst Phil Nadeau has maintained their bullish stance on KZR stock, giving a Buy rating today. Phil Nadeau has given his Buy rating due ...

Buy Rating Affirmed for Kezar Life Sciences Amidst Strong Clinical Progress and Strategic Focus

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), Achiev...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Kezar Life Sciences

Kezar Life Sciences (KZR) Forecast

Kezar Life Sciences (NASDAQ:KZR) Stock, Quote.Headers.trade-ideas